P055 IMPACT OF NEW BIOLOGIC AGENT APPROVAL FOR ULCERATIVE COLITIS ON TUMOR NECROSIS FACTOR INHIBITOR (TNF) PRESCRIBING: RESULTS FROM A NATIONAL PATIENT CHART AUDIT

TNF-inhibitor (TNF) therapy was approved for use in moderately active ulcerative colitis (UC) in 2005. We were interested in studying to what extent newly approved biologics with a different mechanism of action (MOA) had on utilization.